Vioxx Promotions, Labeling Revisions Are Focus Of Drug Safety Hearing

Three FDAers and Merck VP Erb will testify at the House Government Reform Committee hearing May 5. The committee suggests that creation of a Drug Safety Monitoring Board will not resolve all concerns with FDA’s post-marketing surveillance.